Company Filing History:
1 out of 1,933 
2 out of 833,002 Years Active: 1998-2002
Title: Hiromitsu Sahara: Innovator in Gastric Cancer Research
Introduction
Hiromitsu Sahara is a notable inventor based in Rishirifuji-machi, Japan. He has made significant contributions to the field of medical research, particularly in the area of gastric cancer treatment. With a total of 2 patents, his work focuses on innovative peptides that can induce immune responses against human gastric cancer.
Latest Patents
Sahara's latest patents include a peptide capable of inducing an immune response to human gastric cancer. This peptide is designed to induce cytotoxic T lymphocytes (CTL) against human gastric cancer cells. The specific amino-acid sequence of the peptide allows it to target gastric cancer cells effectively, making it a potential agent for preventing or treating this type of cancer.
Career Highlights
Throughout his career, Hiromitsu Sahara has worked with prominent companies, including Ajinomoto Co., Ltd. His research has been pivotal in advancing the understanding of immune responses in cancer treatment. His innovative approach has opened new avenues for therapeutic interventions in gastric cancer.
Collaborations
Sahara has collaborated with esteemed colleagues such as Kokichi Kikuchi and Noriyuki Sato. These partnerships have enriched his research and contributed to the development of effective cancer treatment strategies.
Conclusion
Hiromitsu Sahara's work in developing peptides for gastric cancer treatment showcases his dedication to medical innovation. His contributions are vital in the ongoing fight against cancer, and his patents reflect a promising future for therapeutic advancements in this field.